Wedbush Research Analysts Lift Earnings Estimates for KNSA

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Stock analysts at Wedbush boosted their Q1 2025 EPS estimates for shares of Kiniksa Pharmaceuticals in a note issued to investors on Monday, January 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $0.10 for the quarter, up from their prior estimate of $0.09. Wedbush currently has a "Outperform" rating and a $34.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals' Q2 2025 earnings at $0.11 EPS, Q3 2025 earnings at $0.15 EPS and FY2025 earnings at $0.56 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The company had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals's quarterly revenue was up 67.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.20) earnings per share.

KNSA has been the topic of several other research reports. Evercore ISI increased their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. raised their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA stock traded down $0.43 during trading on Thursday, reaching $18.39. The company had a trading volume of 424,395 shares, compared to its average volume of 506,150. The firm's 50 day simple moving average is $20.85 and its two-hundred day simple moving average is $23.24. Kiniksa Pharmaceuticals has a one year low of $16.56 and a one year high of $28.15. The company has a market capitalization of $1.33 billion, a PE ratio of -131.35 and a beta of 0.29.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the firm's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the sale, the chief operating officer now directly owns 88,975 shares in the company, valued at $1,622,904. This trade represents a 13.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the business's stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now owns 22,958 shares in the company, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,092 shares of company stock worth $471,609 over the last three months. 54.57% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. raised its holdings in Kiniksa Pharmaceuticals by 1.9% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company's stock valued at $3,947,000 after acquiring an additional 3,673 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Kiniksa Pharmaceuticals by 4.4% in the fourth quarter. Nordea Investment Management AB now owns 194,883 shares of the company's stock valued at $3,818,000 after purchasing an additional 8,257 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at $4,997,000. Franklin Resources Inc. lifted its position in Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock worth $1,798,000 after purchasing an additional 1,100 shares during the period. Finally, XTX Topco Ltd boosted its stake in Kiniksa Pharmaceuticals by 62.2% during the third quarter. XTX Topco Ltd now owns 27,302 shares of the company's stock worth $682,000 after buying an additional 10,474 shares in the last quarter. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.